Valsartan Drug Combination Amlodipine

A pharmaceutical preparation of amlodipine and valsartan that is used for the treatment of HYPERTENSION.

Also Known As:

Amlodipine, Valsartan Drug Combination; Amlodipine - Valsartan; Amlodipine-Valsartan; Amlodipine-Valsartan Drug Combination; Exforge; Amlodipine Valsartan; Amlodipine Valsartan Drug Combination; Combination, Amlodipine-Valsartan Drug; Drug Combination, Amlodipine-Valsartan

Networked: 61 relevant articles (12 outcomes, 26 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Oparil, Suzanne: 5 articles (01/2014 - 12/2009)
2.	Samuel, Rita: 5 articles (08/2011 - 01/2011)
3.	Hilkert, Robert: 5 articles (07/2011 - 08/2009)
4.	Pitt, Bertram: 4 articles (01/2014 - 01/2011)
5.	Glazer, Robert D: 4 articles (08/2013 - 01/2009)
6.	Purkayastha, Das: 4 articles (08/2011 - 01/2011)
7.	Sunkara, Gangadhar: 3 articles (11/2014 - 01/2008)
8.	Zhang, Ying: 3 articles (09/2013 - 07/2010)
9.	Philipp, Thomas: 3 articles (09/2011 - 04/2007)
10.	Yen, Joseph: 3 articles (09/2011 - 04/2007)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/01/2015 - "Real-world data indicate an association of the amlodipine/valsartan/HCT SPC with improved adherence and persistence vs. FC with no difference in overall healthcare or hypertension specific costs between the cohorts." 01/01/2011 - "This randomized, double-blind study evaluated efficacy of a single-pill combination of amlodipine/valsartan (Aml/Val) in Asian patients with hypertension not responding to Val 80 mg. Patients with mean sitting diastolic blood pressure (DBP) ≥90-≤110 mmHg were randomized to Aml/Val 5/80, Val 80, or Val 160 mg for 8 weeks. " 10/01/2020 - "Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial." 09/01/2016 - "Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study." 06/01/2011 - "A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners. "
2.	Dyslipidemias (Dyslipidemia) 09/01/2018 - "The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia."
3.	Essential Hypertension 09/01/2010 - "Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study." 01/01/2009 - "This was a 54-week, multicenter, open-label extension study in patients with mild-to-moderate essential hypertension selected after successfully completing a core study during which they received either placebo, amlodipine, valsartan or combination therapy. " 04/01/2011 - "Patients with essential hypertension, who's ambulatory BP was uncontrolled after 4 weeks on amlodipine (5 mg) were randomized to receive amlodipine/valsartan (5/160 mg) for 8 weeks in the morning or evening (n=231, 232, respectively), with optional uptitration up to 10/160 mg after 4 weeks if the office BP was uncontrolled. " 07/01/2010 - "Exforge HCT is currently indicated for the treatment of essential hypertension, as replacement therapy for adult patients whose blood pressure is adequately controlled by the combination of amlodipine, valsartan and HCTZ."
4.	Isolated Systolic Hypertension 02/01/2011 - "An optimal BP reduction was achieved for all hypertension grades as well as isolated systolic hypertension, providing evidence that most hypertensive patients may benefit from amlodipine/valsartan combination treatment." 02/01/2012 - "This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily. " 08/01/2011 - "Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study."
5.	Overweight 09/01/2013 - "In this study, the effectiveness of amlodipine/valsartan single-pill combination was assessed in hypertensive patients with diabetes, metabolic risk or overweight. "

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	Valsartan (Vals)
3.	Hydrochlorothiazide (Esidrix)
4.	Antihypertensive Agents (Antihypertensives)
5.	Losartan (Cozaar)
6.	Fibric Acids (Fibrates)
7.	Lipids
8.	Angiotensin Receptor Antagonists
9.	Calcium Channel Blockers (Blockers, Calcium Channel)
10.	Calcium

Related Therapies and Procedures

1.	Therapeutics